Skip to content
Their Record

Senate Roll Call 340, 112th Congress · May 24, 2012

To provide substantial savings in health care costs to the Federal government and consumers by fostering competition among generic pharmaceutical manufacturers and ensuring that anti-competitive "pay-for-delay" settlements between brand-name and generic pharmaceutical manufacturers do not block generic drugs from entering the market.

Question before the chamber: On the Amendment

28 yea · 67 nayAmendment Rejected5 not voting or present
Democrat24 yea · 24 nay
Republican3 yea · 41 nay
Independent1 yea · 2 nay

Solid = yea, faded = nay.

The measure

S. 3187 ↗

Food and Drug Administration Safety and Innovation Act

Policy area: Health — assigned by Library of Congress subject specialists, not by this site.

How this vote is scored

Which tracked issues this roll call counts toward, and which way a yea vote moves a member on each. Direction is decided per issue, because one bill can push two issues opposite ways.

  • Health CareDirection unreadable — not scored

    excluded:model-unclear (0.90) Generic drug competition addresses drug pricing rather than health coverage expansion or restriction.

    Tagged by: policy-area:Health

    Axis: Expand coverage ← → Restrict coverage

Who voted which way

Every member recorded on this roll call, with the party they sat with at the time.

Yea (28)

Nay (67)

Not voting or present (5)

Vote records come from Voteview (voteview.com); bill titles and policy areas from the congress.gov API. See methodology for how the record was built.